P. E. Murray¹, F. Garcia-Godoy¹

Molecular & Cellular Biomechanics, Vol.3, No.4, pp. 139-140, 2006, DOI:10.32604/mcb.2006.003.139

Abstract This article has no abstract. More >

Michel Jourdan¹, Karène Mahtouk¹, Jean-luc Veyrune², Guilhem Couderc², Geneviève Fiol², Nicole Redal², Christophe Duperray¹, John De Vos^1,2, Bernard Klein^1,2

European Cytokine Network, Vol.16, No.1, pp. 57-64, 2005

Abstract Primary myeloma cells rapidly apoptose as soon as they are removed from their bone-marrow environment. A likely explanation is that the tumor environment produces survival factors that may counteract a spontaneous activation of pro-apoptotic program. Additional factors may trigger cell cycling in surviving myeloma cells. Interleukin-6 (IL-6) is a well recognized myeloma cell growth factor produced mainly by the tumor environment. However, myeloma cells themselves may produce low levels of autocrine IL-6. The respective roles of paracrine versus autocrine IL-6 are a matter of debate. We investigated these roles using the XG-6 myeloma cell line… More >

Kaouther Snoussi¹, A. Donny Strosberg², Noureddine Bouaouina^1,3, Slim Ben Ahmed⁴, Lotfi Chouchane¹

European Cytokine Network, Vol.16, No.4, pp. 253-260, 2005

Abstract Objectives. Interleukin-1 (IL-1) and interleukin-6 (IL-6) are determining factors in the immune and inflammatory responses to tumors cells. Experimental data suggest that interleukin-1 and interleukin-6 play important roles in the development and progression of breast cancer. We designed a broad study to investigate the susceptibility and prognostic implications of the genetic variation in IL-1α, IL-1β and IL-6 in breast carcinoma. Experimental design. We used the polymerase chain reaction and restriction enzyme digestion to characterize the genetic variation of IL-1α, IL-1β and IL-6 in 305, unrelated Tunisian patients with breast carcinoma and 200 healthy control subjects.… More >

Jean-Jacques Lataillade¹, Jorge Domenech², Marie-Caroline Le Bousse-Kerdilès³

European Cytokine Network, Vol.15, No.3, pp. 177-188, 2004

Abstract Generation of haematopoietic cells is regulated by cellular and humoral interactions in which stromal cells, adhesion molecules, cytokines and chemokines play a crucial role. Among the chemokines, SDF-1 and its CXCR4 receptor have been reported to be key players in the nesting of haematopoietic progenitors within the bone marrow. Disruption of the SDF-1/CXCR4 axis results in cell mobilization and may participate in leukaemia extramedullary infiltration. In this review we will discuss the manifold roles of the SDF-1 chemokine and of its receptor in haematopoiesis regulation. By recruiting quiescent progenitors, by participating in their survival/cycling and More >

Michael L. Pianezza¹, Steven Rubin², Juan Bass², Shirley Chou², John G. Pike¹, Michael P. Leonard¹

Canadian Journal of Urology, Vol.11, No.1, pp. 2151-2156, 2004

Abstract Background: Wilms' Tumor is the most common malignant neoplasm of the urinary tract in children. Since 1969, the National Wilms' Tumor Study Group (NWTSG) has contributed to improving the clinical management and outcome of children affected by Wilms' Tumor. We have managed our patients according to NWTSG protocols and report our results herein.
Methods: Retrospective chart review of consecutive patients presenting at the Children's Hospital of Eastern Ontario (CHEO) with a diagnosis of Wilms' Tumor between April 1990 and March 2001.
Results: Forty patients with Wilms' Tumor (18 M/22 F) were diagnosed at CHEO during this interval. Mean… More >

Anita W. Rijneveld^1,2,*, Sandrine Florquin³, Peter Speelman^2,4, Carl K. Edwards⁵, Charles A. Dinarello⁶, Tom van der Poll^2,4

European Cytokine Network, Vol.14, No.4, pp. 242-245, 2003

Abstract The inhibition of the biological activity of IL-1 by recombinant human IL-1 receptor antagonist (IL-1ra) has been investigated in several, controlled clinical trials. Encouraging results have been reported, in particular in patients with rheumatoid arthritis. In the present study, we investigated the influence of treatment of wild type mice with IL-1ra, which resulted in an incomplete and transient inhibition of IL-1 activity. Treatment with recombinant human IL-1ra resulted in an enhanced bacterial outgrowth in the lungs of BALB/c and C57BL/6 mice early after induction of pneumococcal pneumonia, without influencing survival or the pulmonary inflammatory response. More >

Armen G Aprikian¹, Neil Fleshner², Adrian Langleben³, Jeffrey Hames⁴

Canadian Journal of Urology, Vol.10, No.5, pp. 1986-1994, 2003

Abstract Objectives: To provide context in oncology for the significance of the benefits and cost of combined androgen blockade (CAB) in the treatment of advanced prostate cancer.
Methods: Canadian drug costs for the survival benefit with CAB in advanced prostate cancer were compared with the costs of benefit with new treatments in advanced non-small-cell lung cancer (NSCLC), metastatic colorectal cancer, and metastatic breast cancer. Clinical toxicities were also compared.
Results: The survival benefit with CAB in advanced prostate cancer appears to be approximately 3 months. The survival benefit with the addition of vinorelbine to cisplatin for the treatment of… More >

Yves Fradet

Canadian Journal of Urology, Vol.9, Suppl.1, pp. 8-13, 2002

Abstract Many methods exist to define high-risk prostate cancer. These include clinical stage, serum PSA, and pathological features such as Gleason score and the number of positive biopsies. Partin tables are widely used to stratify patients according to risk of adverse pathological features at surgery, and to identify those more likely to remain free of recurrent disease following surgery. The priority in most patients with localized prostate cancer remains the selection of a treatment that will provide them with the best chance for cure. While treatment-related morbidity is an important issue, we believe that side effects… More >